Skip to main content

Table 1 Survival by risk groups of 356 patients treated with HD IL-2 alone

From: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

 

Favorable

Intermediate

Poor

Median OS (months) (95% CI)

64.5 (39.4–112)

57.6 (34.5–62)

14 (4–58)

2 year OS from IL-2 treatment

73.8%

63.7%

39.8%

  1. OS overall survival, 95% CI 95% confidence intervals, HD high dose, IL-2 Interleukin-2
Back to article page